The state’s Department of Health and Human Services this week sent letters to firms that did not provide required information about production costs, marketing and advertising costs, patient assistance programs, wholesale acquisition costs, and historical increases, among other information.
Last week, Nevada told 21 diabetes drug manufacturers the state wants $17.4 million in penalties for noncompliance with a new price transparency law.
According to press reports, the state’s Department of Health and Human Services this week sent letters to firms that did not provide required information about production costs, marketing and advertising costs, patient assistance programs, wholesale acquisition costs, and historical increases, among other information.
Thirteen companies were assessed $910,000, followed by Daiichi Sankyo, which was assessed a $735,000, which was the smallest penalty.
According to a state drug transparency report released earlier this year, about 12.6% of adults in Nevada have diabetes, and 1 in 4 don’t know that they have the disease. Direct and indirect diabetes related expenses cost $2.7 billion in the state.
The transparency law requires that manufacturers divulge justifications for price increases; the most cited reason research and development investments, followed by claims that the drug has more competitive value, changes in marketplace dynamics, rebates provided to pharmacy benefit managers (PBMs), insurers, and others, and manufacturing investments.
The Nevada law requires that PBM managers report rebates in aggregate (but not for individual drugs).
A recent study said these laws are largely ineffective at revealing true transaction prices for drugs, though policy makers have hailed these legislative solutions as steps toward bringing down the high cost of drugs for US patients. The laws do not require the release of real price information, including discounts and rebates, by all players in the supply chain.
The Nevada Independent, a nonprofit news organization, reported that the companies have 30 days to either pay the fines in full or 10 days to request an informal dispute resolution meeting with the state. If the companies don’t respond at all, the department will refer the cases to the attorney general’s office to seek a court order to collect the penalty.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.